Publication date: Jul 19, 2024
Participants in studies investigating COVID-19 vaccines commonly report reactogenicity events, and concerns about side effects may lead to a reluctance to receive updated COVID-19 vaccinations. A real-world, post hoc analysis, observational 2019nCoV-406 study was conducted to examine reactogenicity within the first 2 days after vaccination with either a protein-based vaccine (NVX-CoV2373) or an mRNA vaccine (BNT162b2 or mRNA-1273) in individuals who previously completed a primary series. Propensity score adjustments were conducted to address potential confounding. The analysis included 1130 participants who received a booster dose of NVX-CoV2373 (n = 303) or an mRNA vaccine (n = 827) during the study period. Within the first 2 days after vaccination, solicited systemic reactogenicity events (adjusted) were reported in 60. 5% of participants who received NVX-CoV2373 compared with 84. 3% of participants who received an mRNA vaccine; moreover, 33. 9% and 61. 4%, respectively, reported ≥3 systemic reactogenicity symptoms. The adjusted mean (95% CI) number of systemic symptoms was 1. 8 (1. 6-2. 0) and 3. 2 (3. 0-3. 4), respectively. Local reactogenicity events (adjusted) were reported in 73. 4% and 91. 7% of participants who received NVX-CoV2373 and mRNA vaccines, respectively; the adjusted mean (95% CI) number of local symptoms was 1. 5 (1. 33-1. 61) and 2. 4 (2. 31-2. 52), respectively. These results support the use of adjuvanted, protein-based NVX-CoV2373 as an immunization option with lower reactogenicity than mRNAs.
Open Access PDF
| Concepts | Keywords |
|---|---|
| 2019ncov | booster |
| Bnt162b2 | COVID-19 |
| Confounding | mRNA |
| Vaccines | NVX-CoV2373 |
| reactogenicity | |
| real-world evidence | |
| SARS-CoV-2 |